Exocrine pancreatic insufficiency
Methodology & AI Transparency ⓘ
Exocrine pancreatic insufficiency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code K86.81 in Liver & Hepatology, Exocrine pancreatic insufficiency requires comprehensive hepatic panel [Exocrine pancreatic insufficiency K86.81] so specialists can calibrate treatment intensity against FIB-4 Hepatic Fibrosis in Exocrine pancreatic insufficiency (K86.81: Index) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry K86.81: Exocrine pancreatic insufficiency is managed within Liver & Hepatology.
- 3 Typical cash cost range: Primary evaluation for Exocrine pancreatic insufficiency incorporates comprehensive hepatic panel [Exocrine pancreatic insufficiency K86.81] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Exocrine pancreatic insufficiency: FIB-4 Hepatic Fibrosis in Exocrine pancreatic insufficiency (K86.81: Index) (< 1.30 (K86.81)) and Total Bilirubin & in Exocrine pancreatic insufficiency (K86.81: Albumin).
Ask our AI Specialists anything about Exocrine pancreatic insufficiency
What Is Exocrine pancreatic insufficiency?
Cataloged under federal diagnostic code K86.81 in Liver & Hepatology, Exocrine pancreatic insufficiency requires comprehensive hepatic panel [Exocrine pancreatic insufficiency K86.81] so specialists can calibrate treatment intensity against FIB-4 Hepatic Fibrosis in Exocrine pancreatic insufficiency (K86.81: Index) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in liver & hepatology, Exocrine pancreatic insufficiency (K86.81) involves or premature pancreatic in Exocrine pancreatic insufficiency (K86.81: acinar zymogen activation). progression correlates with shifts in FIB-4 Hepatic Fibrosis in Exocrine pancreatic insufficiency (K86.81: Index) (< 1.30 (K86.81)).
Common Symptoms & Clinical Signs
- • Presentation of Exocrine pancreatic insufficiency (K86.81): right upper quadrant in Exocrine pancreatic insufficiency (K86.81: fullness or sharp)
- • Secondary Exocrine pancreatic insufficiency clinical sign: unexplained fatigue, pruritus [Exocrine pancreatic insufficiency K86.81]
- • Symptom flares in Exocrine pancreatic insufficiency correlating with FIB-4 Hepatic Fibrosis in Exocrine pancreatic insufficiency (K86.81: Index) deviation outside < 1.30 (K86.81)
- • Functional liver & hepatology impact requiring comprehensive hepatic panel [Exocrine pancreatic insufficiency K86.81] evaluation (K86.81)
Exocrine pancreatic insufficiency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K86.81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Liver, Gallbladder & Pancreatic Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: FIB-4 Hepatic Fibrosis in Exocrine pancreatic insufficiency (K86.81: Index) | < 1.30 (K86.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total Bilirubin & in Exocrine pancreatic insufficiency (K86.81: Albumin) | Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (K86.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipase & in Exocrine pancreatic insufficiency (K86.81: Triglycerides) | Normal enzymatic baseline (K86.81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Exocrine pancreatic insufficiency
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Pancrelipase Lipase, Pancrelipase Protease, Pancrelipase Amylase Zenpep • RxCUI 1594671 | FDA Prescription Therapeutic Agent | 86% | $4.1778 | $ 177.70 /mo |
| Pancrelipase Pertzye, Creon • RxCUI 1294122 | FDA Prescription Therapeutic Agent | 83% | $2.6645 | $ 116.41 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Exocrine pancreatic insufficiency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Macronutrient intake, appetite, food preferences and exocrine pancreas function Both GLP-1 RAs comparably affected body weight, energy and macronutrient intake. Diabetes, obesity & metabolism • 2021-10-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 34189834 ↗ |
| Can This Approach Help? Inside the Latest Research on Perioperative rifaximin is not associated with enhanced functional and volumetric Further, no significant difference was found in terms of any other endpoints of functional liver- and volume regeneration or perioperative surgical complications following the application of rifaximin versus no intervention. Scientific reports • 2021-09-09 • Phase III Randomized Trial | N = 45 | 82/100 | PMID 34504196 ↗ |
| Can This Approach Help? Inside the Latest Research on Controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and There was no difference in survival found between the group of the perioperative chemotherapy plus cetuximab and that of the postoperative chemotherapy in the cohort of our study. Langenbeck's archives of surgery • 2022-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35211831 ↗ |
Exocrine pancreatic insufficiency Patient Community & “People Like Me” Threads
Filter Exocrine pancreatic insufficiency community threads and patient logs by age, biological sex, dosage, and treatment duration.